Key Takeaways
- The partnership between Moffitt Cancer Center and CMIC Group aims to accelerate global cancer clinical trials, improving patient outcomes by increasing access to innovative treatments across the U.S. and Asia-Pacific regions.
- Moffitt will serve as the primary U.S. clinical trial site for CMIC-managed studies, while CMIC will handle clinical trial management for Moffitt in Japan and other APAC countries, facilitating cross-border research collaboration.
- This collaboration enhances the global reach of both organizations, expanding the diversity of trial participants and expediting the development of groundbreaking cancer therapies.
Moffitt Cancer Center, a global leader in cancer treatment and research, has announced a strategic partnership with CMIC Group, a prominent contract research organization (CRO) in the Asia-Pacific region. This collaboration is designed to accelerate cancer clinical trials and improve patient outcomes worldwide by facilitating cross-border research and increasing access to innovative therapies.
As part of the agreement, Moffitt will serve as a key U.S. clinical trial site for studies managed by CMIC, utilizing its expertise to identify and enroll eligible patients for breakthrough cancer treatments. In return, CMIC will manage Moffitt’s and its partners’ clinical trials in Japan and other major APAC countries, providing crucial support for cross-border clinical research. The partnership aims to expand the diversity of trial participants and expedite the development of innovative cancer therapies, furthering both organizations’ commitment to advancing global cancer research.
CMIC and Moffitt Partnership Expands Global Access to Cutting-Edge Cancer Clinical Trials
CMIC, Japan’s largest clinical CRO, operates in 12 APAC countries and offers comprehensive services in drug development, clinical site management, regulatory consulting, and more. With a strong presence in the Asia-Pacific region, CMIC brings a wealth of experience in managing clinical trials for various therapeutic areas. This partnership allows CMIC to offer its clients faster and easier access to Moffitt’s U.S.-based trial programs, enhancing the global reach of its services.
“This partnership allows us to significantly expand the portfolio of cutting-edge clinical trials available to our patients while providing easy and rapid access for CMIC customers who need a U.S. site for clinical trials,” said Xavier Avat, Chief Business Officer at Moffitt. “Our collaboration with CMIC will also streamline the process for U.S.-based programs preparing regulatory plans in Japan, utilizing CMIC Group’s expertise in navigating the complexities of clinical trial management across the Asia-Pacific region.”
Moffitt and CMIC Collaborate to Accelerate Cancer Research and Advance Global Patient Care
Moffitt Cancer Center is a National Cancer Institute-designated Comprehensive Cancer Center, renowned for its pioneering research and commitment to improving cancer care through clinical trials and personalized medicine. The center continues to lead advancements in immunotherapy, cell and gene therapy, and precision oncology, making a global impact through innovative partnerships like the one with CMIC.
“We are excited to join forces with Moffitt Cancer Center,” said Teruyoshi Okuda, co-head of CMIC CRO business. “This strategic collaboration will enhance our ability to leverage Moffitt’s expertise in cancer research and cell and gene therapy for our Asia-Pacific customers. It underscores the shared vision of Moffitt and CMIC to advance global healthcare and bring cutting-edge research and clinical solutions to a broader audience.”
Through this partnership, Moffitt and CMIC aim to accelerate the pace of cancer research, improve patient care across continents, and contribute to the development of breakthrough therapies that offer new hope to patients worldwide.
Resource: Moffitt Cancer Center, September 17, 2024
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
